Inactivation of Influenza B Virus by Normal Guinea-pig Serum

References

1. Ananthanaryan R., Paniker C. J. K. 160 Non-specific inhibitors of influenza viruses in normal sera. Bulletin of the World Health Organization 22:409–420
   [Google Scholar]
2. Beebe D. p., Schriber R. D., Cooper N. R. 1983; Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. Journal of Immunology 130:1317–1322
   [Google Scholar]
3. Chu C. M. 1951; The action of normal mouse serum on influenza virus. Journal of General Microbiology 5:739–757
   [Google Scholar]
4. Cooper N. R. 1979; Humoral immunity to viruses. In Comprehensive Virology 15 pp 123–164 Fraenkel-Conrat H., Wagner R. R. Edited by New York & London: Plenum Press;
   [Google Scholar]
5. Cooper N. R. 1984; The role of the complement system in host defense against virus diseases. In Concepts in Viral Pathogenesis pp 20–25 Notkins A. L., Oldstone M. B. A. Edited by New York, Berlin, Heidelberg & Tokyo: Springer-Verlag;
   [Google Scholar]
6. Fearon D. T., Austen K. f. 1977; Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Immunology 74:1683–1687
   [Google Scholar]
7. Francis T. Jr 1947; Dissociation of hemagglutinating and antibody measuring capacities of influenza virus. Journal of Experimental Medicine 85:1–7
   [Google Scholar]
8. Gigli I., Porter R. R., Sim P. B. 1976; The unactivated form of the first component of human complement, Cl. Biochemical Journal 157:541–548
   [Google Scholar]
9. Hawkes R., Niday E., Gordon J. 1982; A dot-immunobinding assay for monoclonal and other antibodies. Analytical Biochemistry 119:142–147
   [Google Scholar]
10. Inai S., Nagaki K., Ebisu S., Kato K., Kotani S., Misaki A. 1976; Activation of the alternative complement pathway by water-insoluble glucans of streptococcus mutants: the relation between their chemical structures and activating potencies. Journal of Immunology 117:1256–1260
    [Google Scholar]
11. Krizanova O., Rathova V. 1969; Serum inhibitors of myxoviruses. Current Topics in Microbiology and Immunology 47:125–151
    [Google Scholar]
12. Maeno K., Kilbourne E. D. 1970; Developmental sequence and intracellular site of synthesis of three structural protein antigens of influenza A2 virus. Journal of Virology 5:153–164
    [Google Scholar]
13. Shibata M., Maeno K., Tsurumi T., Aoki H., Nishiyama Y., Ito Y., Isomura S., Suzuki S. 1982a; Role of viral glycoprotein in haemolysis by influenza B virus. Journal of General Virology 59:183–186
    [Google Scholar]
14. Shibata M., Maeno K., Isomura S., Tsurumi T., Aoki H., Suzuki S. 1982b; Plaque formation by influenza B virus in a porcine kidney cell line. Microbiology and Immunology 26:441–444
    [Google Scholar]
15. Shimojo H., Sugiura A., Akao J., Enomoto C. 1958; Studies of a non-specific hemagglutination inhibitor of influenza A (Asian) 57 virus. Bulletin of the Institute of Public Health 7:219–224
    [Google Scholar]
16. Sissons J. G. P. 1984; Antibody- and complement-dependent lysis of virus-infected cells. In Concepts in Viral Pathogenesis pp 39–45 Notkins A. L., Oldstone M. B. A. Edited by New York, Berlin, Heidelberg & Tokyo: Springer-Verlag;
    [Google Scholar]
17. Sugiura A., Shimojo H., Enomoto C. 1961; Studies of the non-specific hemagglutination inhibitor against influenza A2 virus (gamma-inhibitor). II. Physicochemical properties of the gamma-inhibitor. Japanese Journal of Experimental Medicine 31:159–168
    [Google Scholar]